Companion Diagnostics Partnering Terms & Agreements

Current Partnering
April 1, 2014
379 Pages - SKU: WWV5226178
Companion Diagnostics Partnering Terms & Agreements

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 250 links to online copies of actual companion diagnostics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of companion diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading companion diagnostics deals since 2009. Deals are listed by headline value and signed by big pharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies where companion diagnostic deals are available followed by a brief summary as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of companion diagnosticss partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since January 2009. The chapter is organized by companion diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostics partnering and dealmaking since 2009. The Appendix toward the end includes all the companion diagnostics deals since 2009 by company A-Z, deal type and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostics technologies and products.

Report scope

Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.

  • Trends in companion diagnostics dealmaking in the biopharma industry since 2009
  • Analysis of companion diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life companion diagnostics deals
  • Access to companion diagnostics contract documents
  • The leading companion diagnostics deals by value since 2009
  • Most active companion diagnostics dealmakers since 2009
  • The leading companion diagnostics partnering resources
In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following:
  • What are the precise companion diagnostics rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?



More Companion Diagnostics reports by Current Partnering

Companion Diagnostics Deals and Alliances of 2013 by Current Partnering
Companion Diagnostics Deals and Alliances of 2013The Companion Diagnostics Deals and Alliances of 2013 report provides comprehensive understanding and unprecedented access to the partnering deals ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 1,995  
    CD-ROM Mail Delivery  USD 2,495  
    Multi User License (2-5 Users)  USD 2,995  
    Global Site License  USD 9,995  
    Site License (6+ users at one location)  USD 5,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!